Literature DB >> 18407647

Introduction of functional groups into peptides via N-alkylation.

O Demmer1, I Dijkgraaf, M Schottelius, H-J Wester, H Kessler.   

Abstract

An optimized protocol for the mild and selective Fukuyama-Mitsunobu reaction was used for mono- and di- N-alkylation on solid support. Thereby, nonfunctionalized aliphatic and aromatic residues are quickly introduced into transiently protected, primary amines of a linear peptide. N-Alkylation can also be used to implement alkyl chains carrying (protected) functionalities suited for subsequent modification. Applicability of this method is demonstrated by various N-alkylated analogues of a cyclic CXCR4 receptor antagonist originally developed by Fujii et. al.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407647     DOI: 10.1021/ol800654n

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  10 in total

1.  Solid phase synthesis of a functionalized bis-peptide using "safety catch" methodology.

Authors:  Conrad T Pfeiffer; Christian E Schafmeister
Journal:  J Vis Exp       Date:  2012-05-15       Impact factor: 1.355

2.  Solid-phase synthesis of diverse peptide tertiary amides by reductive amination.

Authors:  Kevin Pels; Thomas Kodadek
Journal:  ACS Comb Sci       Date:  2015-02-25       Impact factor: 3.784

3.  PET imaging of CXCR4 receptors in cancer by a new optimized ligand.

Authors:  Oliver Demmer; Eleni Gourni; Udo Schumacher; Horst Kessler; Hans-Jürgen Wester
Journal:  ChemMedChem       Date:  2011-07-20       Impact factor: 3.466

Review 4.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

5.  Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Authors:  Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger
Journal:  Theranostics       Date:  2015-03-01       Impact factor: 11.556

6.  A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.

Authors:  Theresa Osl; Alexander Schmidt; Markus Schwaiger; Margret Schottelius; Hans-Jürgen Wester
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

7.  CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett's esophagus.

Authors:  Sabrina Marcazzan; Marcos J Braz Carvalho; Matthias Konrad; Julia Strangmann; Anna Tenditnaya; Theresa Baumeister; Roland M Schmid; Hans-Jürgen Wester; Vasilis Ntziachristos; Dimitris Gorpas; Timothy C Wang; Margret Schottelius; Michael Quante
Journal:  EJNMMI Res       Date:  2022-01-10       Impact factor: 3.138

8.  The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity.

Authors:  Andreas Poschenrieder; Margret Schottelius; Markus Schwaiger; Horst Kessler; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2016-04-26       Impact factor: 3.138

9.  First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo.

Authors:  Andreas Poschenrieder; Theresa Osl; Margret Schottelius; Frauke Hoffmann; Martina Wirtz; Markus Schwaiger; Hans-Jürgen Wester
Journal:  Tomography       Date:  2016-06

Review 10.  CXCR4-directed theranostics in oncology and inflammation.

Authors:  Malte Kircher; Peter Herhaus; Margret Schottelius; Andreas K Buck; Rudolf A Werner; Hans-Jürgen Wester; Ulrich Keller; Constantin Lapa
Journal:  Ann Nucl Med       Date:  2018-08-13       Impact factor: 2.668

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.